BREAKING NEWS: New drug approved by the FDA for Duchenne muscular dystrophy. Learn more about this new treatment option.

Innovations in Care

We provide access to support and programs that empower the lives of people living with neuromuscular diseases.

MDA Engage: Myasthenia Gravis Symposium

September 12, 2020MDA Engage Logo
Time: 11:00am - 4:00pm ET / 8:00am - 1:00pm PT
Virtual, online event

There is no cost to members of the MDA community or healthcare providers to attend the event, however registration is required. Members of the biopharma industry interested in sponsoring or attending should contact the MDA Healthcare Partnerships team. For all other questions, please reach out to mdaengage@mdausa.org.

Watch recorded seminar

Agenda

  • MDA Mission Spotlight (11:00am ET)
  • Keynote Presentation: Pediatric Care in MG(11:15am ET)
    • Dr. Emmanuelle Tiongson, Pediatric Neurologist, Clinical Assistant Professor-Division of Neurology, Children’s Hospital Los Angeles
  • Drug Development Roundtable Discussion (12:10pm)
  • Clinical Trials Update (1:00pm ET)
    • Dr. Amit Sachdev, Assistant Professor; Director of the Division of Neuromuscular Medicine, Michigan State University
  • Research Update (1:50pm ET)
    • Dr. Gil Wolfe, Irvin and Rosemary Smith Professor and Chairman, Univ. at Buffalo/SUNY
  • Therapeutic approaches with Subtypes of MG (2:40 pm ET)
    • Dr. Anthony A. Amato, BWH Distinguished Chair in Neurology Chief, Neuromuscular Division Brigham and Women’s Hospital, Professor of Neurology Harvard Medical School
  • Exercise and MG (3:25pm ET)
    • Dr. Charlene Hafer-Macko, Associate Professor of Neurology, University of Maryland School of Medicine

 

Thank you to our supporters:

  • Argenx
  • Momenta Pharma
  • Alexion
  • UCB Community Health Fund
  • Immunovant

For questions reach out to: mdaengage@mdausa.org | 1-833-ASK-MDA1 (1-833-275-6321)